Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + dexamethasone + doxorubicin induction before reduced-intensity ASCT in older patients with multiple myeloma
2009-016610-24Phase 2Active
- Sponsor
- Fondazione EMN Italy
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib, doxorubicin and dexamethasone in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoints: Effect of free or pegylated liposomal doxorubicin on bortezomib pharmacodynamics and Effect of bortezomib on plasma pharmacokinetics of doxorubicin. Started Dec 2009; status: active.
02
Drugs
bortezomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-016610-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016610-24.